Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer

Guillermo Valenzuela, Mauricio Burotto, Katherine Marcelain, Jaime González-Montero*

*Autor correspondiente de este trabajo

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

Resumen

Colorectal cancer (CRC) is a major cause of mortality worldwide, associated with a steadily growing prevalence. Notably, the identification of KRAS, NRAS, and BRAF mutations has markedly improved targeted CRC therapy by affording treatments directed against the epidermal growth factor receptor (EGFR) and other anti-angiogenic therapies. However, the survival benefit conferred by these therapies remains variable and difficult to predict, owing to the high level of molecular heterogeneity among patients with CRC. Although classification into consensus molecular subtypes could optimize response prediction to targeted therapies, the acquisition of resistance mutations to targeted therapy is, in part, responsible for the lack of response in some patients. However, the acquisition of such mutations can induce challenges in clinical practice. The utility of liquid biopsy to detect resistance mutations against anti-EGFR therapy has recently been described. This approach may constitute a new standard in the decision algorithm for targeted CRC therapy.

Idioma originalInglés
Páginas (desde-hasta)1654-1664
Número de páginas11
PublicaciónWorld Journal of Gastrointestinal Oncology
Volumen14
N.º9
DOI
EstadoPublicada - 15 sept. 2022
Publicado de forma externa

Nota bibliográfica

Publisher Copyright:
© 2022, Baishideng Publishing Group Inc. All rights reserved.

Huella

Profundice en los temas de investigación de 'Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer'. En conjunto forman una huella única.

Citar esto